Researchers at the University of California, Berkeley, have identified an experimental compound that may offer a new approach to weight-loss treatment by increasing the body's energy expenditure rather than suppressing appetite, as widely used drugs such as Ozempic and Wegovy do. In trials involving mice, the compound raised energy expenditure by up to 18 percent, improved blood-sugar control, reduced liver fat, and produced weight loss without significant muscle loss, according to the research team. The findings, reported in the Science category, suggest a mechanism distinct from existing GLP-1-based therapies and one that may address a common concern among patients and clinicians about losing lean muscle mass during weight loss.
The researchers also reported that combining the compound with existing GLP-1 medications yielded greater benefits than either treatment alone in the animal studies, a result that could inform future combination-therapy strategies. The compound has not yet been tested in humans, and the team cautioned that mouse results do not always translate to people. Further preclinical and clinical studies would be required to establish safety, dosing, and efficacy. The work adds to a growing field of metabolic research aimed at expanding treatment options beyond appetite suppression, though experts note that any new therapy would face years of rigorous testing before regulatory review.
Independent reporting synthesized from primary wires and global correspondents.